Cancer Imaging With Fluorine-18-Labeled Choline Derivatives

Sandi A. Kwee, Timothy R DeGrado, Jean Noel Talbot, Fabrice Gutman, Marc N. Coel

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

The choline transporter and choline kinase enzyme frequently are overexpressed in malignancy. Therefore, positron-emitter-labeled compounds derived from choline have the potential to serve as oncologic probes for positron emission tomography. The fluorine-18 (18F)-labeled choline derivative fluorocholine (FCH) in particular has demonstrated potential utility for imaging of a variety of neoplasms, including those of the breast, prostate, liver, and brain. The pharmacokinetics of FCH and other choline tracers allow for whole-body imaging within minutes of injection while still achieving high tumor-to-background contrast in most organs, including the brain. These features, along with the possibility of imaging malignancies that have proved elusive with the use of 18F-fluorodeoxyglucose positron emission tomography support further clinical investigations of 18F-labeled choline tracers.

Original languageEnglish (US)
Pages (from-to)420-428
Number of pages9
JournalSeminars in Nuclear Medicine
Volume37
Issue number6
DOIs
StatePublished - Nov 2007
Externally publishedYes

Fingerprint

Fluorine
Choline
Positron-Emission Tomography
Neoplasms
Choline Kinase
Whole Body Imaging
Fluorodeoxyglucose F18
Brain
Prostate
Breast
Pharmacokinetics
Electrons
Injections
Liver
Enzymes
fluorocholine
fluoromethylcholine

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Cancer Imaging With Fluorine-18-Labeled Choline Derivatives. / Kwee, Sandi A.; DeGrado, Timothy R; Talbot, Jean Noel; Gutman, Fabrice; Coel, Marc N.

In: Seminars in Nuclear Medicine, Vol. 37, No. 6, 11.2007, p. 420-428.

Research output: Contribution to journalArticle

Kwee, Sandi A. ; DeGrado, Timothy R ; Talbot, Jean Noel ; Gutman, Fabrice ; Coel, Marc N. / Cancer Imaging With Fluorine-18-Labeled Choline Derivatives. In: Seminars in Nuclear Medicine. 2007 ; Vol. 37, No. 6. pp. 420-428.
@article{b0ffd09212434c1bae6dfa50e99cf2e2,
title = "Cancer Imaging With Fluorine-18-Labeled Choline Derivatives",
abstract = "The choline transporter and choline kinase enzyme frequently are overexpressed in malignancy. Therefore, positron-emitter-labeled compounds derived from choline have the potential to serve as oncologic probes for positron emission tomography. The fluorine-18 (18F)-labeled choline derivative fluorocholine (FCH) in particular has demonstrated potential utility for imaging of a variety of neoplasms, including those of the breast, prostate, liver, and brain. The pharmacokinetics of FCH and other choline tracers allow for whole-body imaging within minutes of injection while still achieving high tumor-to-background contrast in most organs, including the brain. These features, along with the possibility of imaging malignancies that have proved elusive with the use of 18F-fluorodeoxyglucose positron emission tomography support further clinical investigations of 18F-labeled choline tracers.",
author = "Kwee, {Sandi A.} and DeGrado, {Timothy R} and Talbot, {Jean Noel} and Fabrice Gutman and Coel, {Marc N.}",
year = "2007",
month = "11",
doi = "10.1053/j.semnuclmed.2007.07.003",
language = "English (US)",
volume = "37",
pages = "420--428",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Cancer Imaging With Fluorine-18-Labeled Choline Derivatives

AU - Kwee, Sandi A.

AU - DeGrado, Timothy R

AU - Talbot, Jean Noel

AU - Gutman, Fabrice

AU - Coel, Marc N.

PY - 2007/11

Y1 - 2007/11

N2 - The choline transporter and choline kinase enzyme frequently are overexpressed in malignancy. Therefore, positron-emitter-labeled compounds derived from choline have the potential to serve as oncologic probes for positron emission tomography. The fluorine-18 (18F)-labeled choline derivative fluorocholine (FCH) in particular has demonstrated potential utility for imaging of a variety of neoplasms, including those of the breast, prostate, liver, and brain. The pharmacokinetics of FCH and other choline tracers allow for whole-body imaging within minutes of injection while still achieving high tumor-to-background contrast in most organs, including the brain. These features, along with the possibility of imaging malignancies that have proved elusive with the use of 18F-fluorodeoxyglucose positron emission tomography support further clinical investigations of 18F-labeled choline tracers.

AB - The choline transporter and choline kinase enzyme frequently are overexpressed in malignancy. Therefore, positron-emitter-labeled compounds derived from choline have the potential to serve as oncologic probes for positron emission tomography. The fluorine-18 (18F)-labeled choline derivative fluorocholine (FCH) in particular has demonstrated potential utility for imaging of a variety of neoplasms, including those of the breast, prostate, liver, and brain. The pharmacokinetics of FCH and other choline tracers allow for whole-body imaging within minutes of injection while still achieving high tumor-to-background contrast in most organs, including the brain. These features, along with the possibility of imaging malignancies that have proved elusive with the use of 18F-fluorodeoxyglucose positron emission tomography support further clinical investigations of 18F-labeled choline tracers.

UR - http://www.scopus.com/inward/record.url?scp=34848926866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848926866&partnerID=8YFLogxK

U2 - 10.1053/j.semnuclmed.2007.07.003

DO - 10.1053/j.semnuclmed.2007.07.003

M3 - Article

C2 - 17920349

AN - SCOPUS:34848926866

VL - 37

SP - 420

EP - 428

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

IS - 6

ER -